Evidence map›Paper›PMID 34573862›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Polyprev: Randomized, Multicenter, Controlled Trial Comparing Fecal Immunochemical Test with Endoscopic Surveillance after Advanced Adenoma Resection in Colorectal Cancer Screening Programs: A Study Protocol.

Cristina Regueiro, Raquel Almazán, Isabel Portillo, María Besó, Carlos Tourne-Garcia, Elena Rodríguez-Camacho, Akiko Ono, Ángel Gómez-Amorín, Joaquín Cubiella

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cristina RegueiroDepartment of Gastroenterology, Instituto de Investigación Sanitaria Galicia Sur, Hospital Universitario de Ourense, 32005 Ourense, Spain.
Raquel AlmazánConselleria de Sanidade, Dirección Xeral de Saúde Pública, 15704 Galicia, Spain.
Isabel PortilloOsakidetza Basque Health Service, Basque Country Colorectal Cancer Screening Programme, 48009 Bilbao, Spain.ORCID 0000-0002-3871-3423
María BesóServicio de Promoción de la Salud y Prevención en el Entorno Sanitario, Dirección General de Salud Pública y Adicciones, 46021 Valencia, Spain.
Carlos Tourne-GarciaColon and Rectal Cancer Prevention Program, Directorate General for Public Health, Autonomous Government for Health, 30008 Mucia, Spain.
Elena Rodríguez-CamachoConselleria de Sanidade, Dirección Xeral de Saúde Pública, 15704 Galicia, Spain.
Akiko OnoDepartment of Gastroenterology, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.
Ángel Gómez-AmorínConselleria de Sanidade, Dirección Xeral de Saúde Pública, 15704 Galicia, Spain.
Joaquín CubiellaDepartment of Gastroenterology, Instituto de Investigación Sanitaria Galicia Sur, Hospital Universitario de Ourense, 32005 Ourense, Spain.ORCID 0000-0002-9994-4831
Xunta de Galicia · ESComplejo Hospitalario de Ourense · ESBioCruces Health research Institute · ESHospital Universitario Virgen de la Arrixaca · ES

Funding

Instituto de Salud Carlos III PI21/01771
6 · The paper itself

Abstract

Colorectal cancer (CRC) screening programs have been implemented to reduce the burden of the disease. When an advanced colonic lesion is detected, clinical practice guidelines recommend endoscopic surveillance with different intervals between explorations. Endoscopic surveillance is producing a considerable increase in the number of colonoscopies, with a limited effect on the CRC incidence. Instead, participation in CRC screening programs based on the fecal immunochemical test (FIT) could be a non-inferior alternative to endoscopic surveillance to reduce 10-year CRC incidence. Based on this hypothesis, we have designed a multicenter and randomized clinical trial within the Spanish population CRC screening programs to compare FIT surveillance with endoscopic surveillance. We will include individuals aged from 50 to 65 years with complete colonoscopy and advanced lesions resected within the CRC screening programs. Patients will be randomly allocated to perform an annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10 µg/g, or to perform endoscopic surveillance. On the basis of the non-superior CRC incidence, we will recruit 1894 patients in each arm. The main endpoint is 10-year CRC incidence and the secondary endpoints are diagnostic yield, participation, adverse effects, mortality and cost-effectiveness. Our results may modify the clinical practice after advanced colonic resection in CRC screening programs.

Indexed as

colorectal cancerendoscopic surveillancefecal immunochemical testscreening programs

Identifiers

PMID34573862
PMCPMC8465973
OpenAlexW3195806377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.